Non-ATP competitive protein kinase inhibitors.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Medicinal Chemistry

• Publication date

  2010-08-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986710791859333PMID 20586715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.

  2010cited by this paper
• The origin of allosteric functional modulation: multiple pre-existing pathways.

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

  2009cited by this paper
• Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.

  2009cited by this paper
• Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

  2009cited by this paper
• Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.

  2009cited by this paper
• A conserved protonation-dependent switch controls drug binding in the Abl kinase

  2009cited by this paper
• Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).

  2009cited by this paper
• Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms

  2009cited by this paper
• Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.

  2009cited by this paper
• Selectivity and therapeutic inhibition of kinases: to be or not to be?

  2009cited by this paper
• Kinase domain mutations in cancer: implications for small molecule drug design strategies.

  2009cited by this paper
• Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

  2009cited by this paper
• Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.

  2009cited by this paper
• Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.

  2008cited by this paper
• Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.

  2008cited by this paper
• Small molecule recognition of c-Src via the Imatinib-binding conformation.

  2008cited by this paper
• Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states.

  2008cited by this paper
• Development of pyridopyrimidines as potent Akt1/2 inhibitors.

  2008cited by this paper
• Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.

  2008cited by this paper
• Allostery: absence of a change in shape does not imply that allostery is not at play.

  2008cited by this paper
• 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).

  2008cited by this paper
• Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.

  2008cited by this paper
• Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.

  2008cited by this paper
• Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.

  2008cited by this paper
• Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.

  2008cited by this paper
• Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.

  2008cited by this paper
• Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

  2008cited by this paper
• The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.

  2008cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• Dual binding site inhibitors of B-RAF kinase.

  2008cited by this paper
• Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.

  2008cited by this paper
• Non-ATP-competitive kinase inhibitors – enhancing selectivity through new inhibition strategies

  2008cited by this paper
• The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

  2008cited by this paper
• Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.

  2008cited by this paper
• Protein kinase inhibitors: structural insights into selectivity.

  2007cited by this paper
• Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.

  2007cited by this paper
• Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

  2007cited by this paper
• Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.

  2007cited by this paper
• Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.

  2007cited by this paper
• Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.

  2007cited by this paper
• Thienopyridine urea inhibitors of KDR kinase.

  2007cited by this paper
• AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma

  2007cited by this paper
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

  2007cited by this paper
• A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.

  2007cited by this paper
• 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.

  2007cited by this paper
• Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases.

  2006cited by this paper
• Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• A general strategy for creating "inactive-conformation" abl inhibitors.

  2006cited by this paper
• Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.

  2005cited by this paper
• Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

  2005cited by this paper
• Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.

  2005cited by this paper
• Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.

  2005cited by this paper
• Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

  2005cited by this paper
• The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Is allostery an intrinsic property of all dynamic proteins?

  2004cited by this paper
• Design and discovery of small molecules targeting raf-1 kinase.

  2002cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper

• Development of Potent Type V MAPK Inhibitors: Design, Synthesis, and Biological Evaluation of Benzothiazole Derivatives Targeting p38α MAPK in Breast Cancer Cells

  2025cites this paper
• Kinases and their derived inhibitors from natural products.

  2025cites this paper
• Tetracyclic homoisoflavanoid (+)-brazilin: a natural product inhibits c-di-AMP-producing enzyme and Streptococcus mutans biofilms

  2024cites this paper
• High-throughput kinetics in drug discovery.

  2024cites this paper
• Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?

  2024cites this paper
• Development of Kinase‐Centric Drugs: A Computational Perspective

  2023cites this paper
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

  2023cites this paper
• Structural insights into N-heterocyclic moieties as an anticancer agent against hepatocellular carcinoma: An exhaustive perspective.

  2023cites this paper
• Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

  2022influential citation
• Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia

  2022cites this paper
• Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity

  2022cites this paper
• OTT_A_289306 103..116

  2022cites this paper
• Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma

  2021cites this paper
• Allosteric Modulation

  2021cites this paper
• MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma

  2021cites this paper
• The In Vitro and In Silico Inhibition Mechanism of Glutathione Reductase by Resorcinol Derivatives: A Molecular Docking Study

  2021cites this paper
• Characterizing an allosteric inhibitor-induced inactive state in with-no-lysine kinase 1 using Gaussian accelerated molecular dynamics simulations.

  2021cites this paper
• High-Throughput Screening For The Discovery Of Enzyme Inhibitors.

  2020cites this paper
• Synthesis and SAR of Tetracyclic Inhibitors of Protein Kinase CK2 Derived from Furocarbazole W16

  2020cites this paper
• Computational insight into the selective allosteric inhibition for PTP1B versus TCPTP: a molecular modelling study

  2020cites this paper
• Should we keep rocking? Portraits from targeting rho kinases in cancer.

  2020cites this paper
• Drug Repurposing in Dentistry: Towards Application of Small Molecules in Dentin Repair

  2020cites this paper
• Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.

  2020cites this paper
• Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage.

  2019cites this paper
• Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient

  2019cites this paper
• Targeting the translational machinery in aggressive cancers

  2019cites this paper
• Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction

  2019cites this paper
• Inhibiting Phosphorylation of Tau (τ) Proteins at Ser262 Using Peptide-Based R1 Domain Mimetics

  2019cites this paper
• Crystal structure of mRIPK3 complexed with N-(3-fluoro-4-{1H-pyrrolo[2,3-b]pyridin-4-yloxy}phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

  2019cites this paper
• The Drug Discovery Process

  2019cites this paper
• The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1

  2019cites this paper
• Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.

  2019cites this paper
• Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

  2019cites this paper
• Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.

  2019cites this paper
• Molecular Brain Adaptations to Ethanol: Role of Glycogen Synthase Kinase-3 Beta in the Transition to Excessive Consumption

  2018cites this paper
• Chemical genetic approach to identify substrates of CK2 kinase using Mass spectrometry

  2018cites this paper
• Kinase-targeted cancer therapies: progress, challenges and future directions

  2018cites this paper
• In silico Analysis of Liriodenine as a Novel ATP-Competitive PIM 1 Inhibitor in some Cancer Cell-Lines of Haematopoietic and Prostate Origins

  2018cites this paper
• Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

  2018cites this paper
• IKKs and tumor cell plasticity

  2018cites this paper
• A multistep docking and scoring protocol for congeneric series: Implementation on kinase DFG-out type II inhibitors.

  2018cites this paper
• QSAR Study and Molecular Docking of 2 Phenylaminoimidazo[4,5-H]Isoquinolin-9-Ones as Potent Inhibitors of P56ick Tyrosine Kinase (LCK) in Breast Cancer Therapy

  2018cites this paper
• A Comprehensive Structural Overview of p38α Mitogen‐Activated Protein Kinase in Complex with ATP‐Site and Non‐ATP‐Site Binders

  2018cites this paper
• AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965

  2018cites this paper
• Protein kinase- and lipase inhibitors of inositide metabolism deplete IP7 indirectly in pancreatic β-cells: Off-target effects on cellular bioenergetics and direct effects on IP6K activity

  2018cites this paper
• Mechanisms of activation and inhibition of the metabolic regulator AMP-activated protein kinase (AMPK)

  2018cites this paper
• A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2

  2018cites this paper
• Mechanistic enzymology in drug discovery: a fresh perspective

  2017cites this paper
• Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I

  2017cites this paper
• ETS-targeted therapy: can it substitute for MEK inhibitors?

  2017cites this paper
• Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement

  2017cites this paper
• Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts

  2017cites this paper
• Thermal Shift as an Entropy-Driven Effect.

  2017cites this paper
• Conformational Control of UDP-Galactopyranose Mutase Inhibition.

  2017cites this paper
• Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

  2017cites this paper
• Targeting protein kinases to manage or prevent Alzheimer’s disease

  2016cites this paper
• Targeting of nucleotide-binding proteins by HAMLET—a conserved tumor cell death mechanism

  2016cites this paper
• DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

  2016cites this paper
• Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.

  2016cites this paper
• Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib.

  2016cites this paper
• Halogen bonds involved in binding of halogenated ligands by protein kinases.

  2016cites this paper
• Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase: In Silico Approach to Identify PPI Inhibitors

  2016cites this paper
• Kinase inhibitors as potential agents in the treatment of multiple myeloma

  2016cites this paper
• Characterization of the catalytic CK2 subunits with substitutions at residues involved in inhibitor binding

  2016cites this paper
• LASSBio‐1829 Hydrochloride: Development of a New Orally Active N‐Acylhydrazone IKK2 Inhibitor with Anti‐inflammatory Properties

  2016cites this paper
• Radiolabeled Tyrosine Kinase Inhibitors for Drug Development and Cancer treatment: TKI-PET

  2016influential citation
• Structure‐based Drug Design Using NMR

  2015cites this paper
• NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors

  2015cites this paper
• AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation

  2015cites this paper
• Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

  2015cites this paper
• Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy

  2015cites this paper
• The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.

  2015cites this paper
• Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.

  2015cites this paper
• Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters.

  2015cites this paper
• A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors

  2015cites this paper
• Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.

  2015cites this paper
• Properties of Protein Drug Target Classes

  2015cites this paper
• A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease

  2015cites this paper
• New Benzimidazoles and Their Antitumor Effects with Aurora A Kinase and KSP Inhibitory Activities

  2015cites this paper
• Distinguishing the interactions in the fructose 1,6-bisphosphate binding site of human liver pyruvate kinase that contribute to allostery.

  2015cites this paper
• p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening

  2015cites this paper
• A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

  2015cites this paper
• Predicting Drug Target Proteins and Their Properties

  2015cites this paper
• Presence and utility of intrinsically disordered regions in kinases.

  2014cites this paper
• Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening

  2014cites this paper
• A FluoPol-ABPP PAD2 High-Throughput Screen Identifies the First Calcium Site Inhibitor Targeting the PADs

  2014cites this paper
• Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

  2014cites this paper
• In Vitro High Throughput Screening, What Next? Lessons from the Screening for Aurora Kinase Inhibitors

  2014cites this paper
• Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

  2014cites this paper
• Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo

  2014influential citation
• The Parkinson Disease-linked LRRK2 Protein Mutation I2020T Stabilizes an Active State Conformation Leading to Increased Kinase Activity*

  2014cites this paper
• 3D-QSAR study on 2,3-dihydroimidazo[4,5]-pyridin-2-one derivatives with a meta substitution pattern as V600EBRAF inhibitors

  2014cites this paper
• TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER ’ S DISEASE : A REVIEW

  2014cites this paper
• Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.

  2014cites this paper
• Computational methods for analysis and inference of kinase/inhibitor relationships

  2014cites this paper
• A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.

  2014cites this paper
• In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

  2014cites this paper
• Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in

  2013cites this paper
• PKD1 3D Structure Model and Docking Studies for New PKD Inhibitors

  2013cites this paper